KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma

PHASE2CompletedINTERVENTIONAL

Enrollment

153

Participants

Timeline

Start Date

March 6, 2019

Primary Completion Date

July 13, 2021

Study Completion Date

January 13, 2022

Conditions

Nasopharyngeal CarcinomaRecurrent or Metastatic

Interventions

DRUG

KL-A167 Injection

KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)

Trial Locations (1)

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors

lead

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

INDUSTRY

NCT03848286 - KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma | Biotech Hunter | Biotech Hunter